If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
IPO Filter
Monitor
IPO today
Advanced Merger Partners (AMPI.U)
Anzu Special Acquisition I (ANZU.U)
Nightdragon Acquisition (NDACU)
Supernova Partners Acquisition II (SNII.U)
Fintech Evolution Acquisition (FTEV.U)
Dhb Capital (DHBCU)
Orion Acquisition Corp. (OHPAU)
Upcoming IPO
Afc Gamma, Inc. (AFCG)
Roth Ch Acquisition III (ROCRU)
Live Oak Mobility Acquisition (LOKM.U)
Property Solutions Acquisition II (PSAGU)
Atlantic Coastal Acquisition (ACAHU)
Khosla Ventures Acquisition Co. (KVSA)
TCW Special Purpose Acquisition Corp. (TSPQ.U)
Aurora Acquisition Corp. (AURCU)
Oscar Health, Inc. (OSCR)
Innovage Holding Corp (INNV)
Roblox Corporation (RBLX)
Coupang, Inc. (CPNG)
Priced IPO
Score Media And Gaming, Inc. (SCR)
Briacell Therapeutics Corp. (BCTX)
Clip Interactive, LLC (AUDD)
Greenbox Pos (GBOX)
Virpax Pharmaceuticals, Inc. (VRPX)
Urban-gro (UGRO)
Neximmune, Inc. (NEXI)
Longeveron (LGVN)
Talis Biomedical Corporation (TLIS)
Decibel Therapeutics, Inc. (DBTX)
Loandepot, Inc. (LDI)
Bumble, Inc. (BMBL)
Apria, Inc. (APR)
Signify Health, Inc.. (SGFY)
Bioventus Inc. (BVS)
Biophytis SA (BPTS)
Vallon Pharmaceuticals (VLON)
Viant Technology Inc. (DSP)
Global Internet of People (SDH)
Baosheng Media Group Holdings (BAOS)
More companies
Kinnate Biopharma Inc. (KNTE)
Sector - Healthcare
Price chart
+69.95%
Return from IPO
Company News
Buy BitcoinIPO Profile
About company
They are a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Their mission is to expand the reach of targeted therapeutics by developing products for underserved populations. They utilize their deep expertise in structure-based drug discovery, translational research and patient-driven precision medicine, which they collectively refer to as their Kinnate Discovery Engine, to develop their targeted therapies. They focus their discovery and development efforts on three patient populations: (1) those with cancers that harbor known oncogenic drivers (gene mutations that cause cancers) with no currently available targeted therapies, (2) those with genomically well-characterized tumors that have intrinsic resistance to currently available treatments, and (3) those whose tumors have acquired resistance over the course of therapy to currently available treatments. They believe their unique approach may enable them to develop drugs with an increased probability of clinical success while reducing the cost and risk of drug development.
Contacts
Address: 11975 El Camino Real, Suite 101 San Diego, CA 92130
Telephone: (858) 299-4699
Web page: http://www.kinnate.com
IPO information
Shares & Volumes
| Shares Initial (MM) | 10 |
|---|---|
| Shares Revised (MM) | 12 |
| Expected offer amount (MM) | $170 |
| Realized offer amount(MM) | $240 |
Financial Data (last reporting year)
| Market Cap (MM) | $830.5 |
|---|---|
| Revenues (MM) | $0 |
| Net Income (Loss) (MM) | $-26.1 |
Voting
What do you think will happen with the KNTE share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)
| IPOs led by the firm | .Pro |
|---|---|
| Profitability of conducted IPOs ? | .Pro |
| 1st day change ? | .Pro |
| Change for the first 3 months ? | .Pro |
| Underwriters |
|---|
| Goldman Sachs/ SVB Leerink / Piper Sandler |
| CO-Managers |
| Wedbush PacGrow |
Sector: Healthcare
Tweets about $KNTE
Google Trends Stats